Array BioPharma (NASDAQ:ARRY) : Traders are bullish on Array BioPharma (NASDAQ:ARRY) as it has outperformed the S&P 500 by a wide margin of 4.02% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.91%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.2% in the last 1 week, and is up 5.7% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -46.77% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $7.24 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $3.50 and the 200 Day Moving Average price is recorded at $3.21.
The stock has recorded a 20-day Moving Average of 7.69% and the 50-Day Moving Average is 11.07%.
Array BioPharma (NASDAQ:ARRY): stock turned positive on Friday. Though the stock opened at $3.71, the bulls momentum made the stock top out at $3.73 level for the day. The stock recorded a low of $3.63 and closed the trading day at $3.71, in the green by 0.82%. The total traded volume for the day was 1,308,275. The stock had closed at $3.68 in the previous days trading.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Array Biopharma Inc, Baum Charles M had sold 25,000 shares worth of $184,500 in a transaction dated May 8, 2015. In this transaction, 25,000 shares were sold at $7.38 per share.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Companys wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.